97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details

臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

636 trials found

diseases per page:

Showing 1 to 10 of 636 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04991324 (ClinicalTrials.gov)	September 2022	27/7/2021	Cholecalciferol Comedication in IBD - the 5C Study	Cholecalciferol Comedication in Chronic Inflammatory Bowel Diseases (Crohn's Disease or Ulcerative C ...	Inflammatory Bowel Diseases	Drug: Vitamin D3	University Hospital, Basel, Switzerland	NULL	Not yet recruiting	18 Years	N/A	All	150	Phase 3	NULL
2	NCT05218850 (ClinicalTrials.gov)	July 1, 2022	20/1/2022	The Use of Butyrate Therapy in Pediatric Ulcerative Colitis	Butyrate Therapy in Pediatric Ulcerative Colitis	Ulcerative Colitis	Drug: Butyrate	Children's Hospital Los Angeles	NULL	Not yet recruiting	7 Years	21 Years	All	10	Phase 1	United States
3	NCT05242484 (ClinicalTrials.gov)	May 20, 2022	15/2/2022	A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Seve ...	A Phase 2b Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter Study to Evaluat ...	Colitis, Ulcerative	Biological: Guselkumab;Biological: Golimumab;Biological: JNJ-78934804	Janssen Research & Development, LLC	NULL	Not yet recruiting	18 Years	65 Years	All	500	Phase 2	United States
4	NCT04314375 (ClinicalTrials.gov)	April 2022	17/3/2020	Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets ...	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Efficacy, ...	Ulcerative Colitis	Drug: Low Dose Budesonide;Drug: High Dose Budesonide;Drug: Placebo	Bausch Health Americas, Inc.	NULL	Not yet recruiting	5 Years	17 Years	All	70	Phase 4	NULL
5	NCT05287126 (ClinicalTrials.gov)	April 2022	10/3/2022	A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis	An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod ...	Ulcerative Colitis	Drug: Etrasimod	Arena Pharmaceuticals	NULL	Not yet recruiting	12 Years	17 Years	All	36	Phase 2	NULL
6	EUCTR2021-002537-41-ES (EUCTR)	08/03/2022	09/03/2022	Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Co ...	A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate ...	Moderate to Severe Active Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code 100 ...	Product Name: Efavaleukin Alfa Product Code: AMG 592 INN or Proposed INN: EFAVALEUKIN ALFA	Amgen Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	320	Phase 2	United States;Taiwan;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;Denmark;Netherlands;C ...
7	NCT05176366 (ClinicalTrials.gov)	March 1, 2022	17/11/2021	Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis	A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem ...	Ulcerative Colitis	Drug: ExoFlo	Direct Biologics, LLC	NULL	Not yet recruiting	18 Years	75 Years	All	10	Phase 1	NULL
8	NCT05239702 (ClinicalTrials.gov)	February 28, 2022	1/12/2021	Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases	A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells ...	Crohn Disease;Ulcerative Colitis;Dermatomyositis;Still Disease;Autoimmune Diseases	Biological: CD7 CAR T-cells	Zhejiang University	Yake Biotechnology Ltd.	Recruiting	N/A	N/A	All	75	Early Phase 1	China
9	NCT05118919 (ClinicalTrials.gov)	February 9, 2022	26/10/2021	A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis	A Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild ...	Ulcerative Colitis	Biological: BGP-014;Biological: Placebo	BioGaia Pharma AB	NULL	Recruiting	18 Years	N/A	All	50	Phase 1/Phase 2	Sweden
10	NCT05186623 (ClinicalTrials.gov)	February 5, 2022	22/12/2021	Prediction Model for Response to Biologics and Small Molecular Agent for UC	Establishment of Prediction Model of Biologics and Small Molecular Agent for Patients With Ulcerativ ...	Ulcerative Colitis	Drug: Vedolizumab , Ustekinumab, or Tofacitinib	Asan Medical Center	NULL	Recruiting	18 Years	79 Years	All	300		Korea, Republic of

First Previous1 2 3 4 5…64Next Last